In human prostate cancer tissues, upregulation of MMPs correlates with the loss of tissue inhibitor of MMP-1 (Brehmer et al., 2003[22]), the metastatic phenotype brings high plasma concentrations of MMP-2 and MMP-9 (Morgia et al., 2005[93]), while MMP-12 participates in bone-tropic metastasis (Nabha et al., 2008[94]). This evidence concerns the gene MMP9 and prostate cancer.